Eli Lilly CEO David Ricks joins ‘Squawk Box’ to discuss the company’s quarterly earnings results, which reported third-quarter adjusted profit and revenue that missed expectations, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, why the company is slashing its full-year adjusted profit guidance, and more.
11:26
Wed, Oct 30 20247:41 AM EDT